- Home
- PRFX vs LIPO Comparison
PRFX vs LIPO Comparison
Compare PRFX & LIPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRFX
- LIPO
- Stock Information
- Founded
- PRFX 2007
- LIPO 2005
- Country
- PRFX Israel
- LIPO United States
- Employees
- PRFX N/A
- LIPO N/A
- Industry
- PRFX Biotechnology: Pharmaceutical Preparations
- LIPO Biotechnology: Pharmaceutical Preparations
- Sector
- PRFX Health Care
- LIPO Health Care
- Exchange
- PRFX Nasdaq
- LIPO Nasdaq
- Market Cap
- PRFX 3.0M
- LIPO 3.1M
- IPO Year
- PRFX 2020
- LIPO 2022
- Fundamental
- Price
- PRFX $2.30
- LIPO $2.58
- Analyst Decision
- PRFX Hold
- LIPO Strong Buy
- Analyst Count
- PRFX 1
- LIPO 1
- Target Price
- PRFX N/A
- LIPO $16.00
- AVG Volume (30 Days)
- PRFX 46.2K
- LIPO 45.6K
- Earning Date
- PRFX 01-01-0001
- LIPO 05-08-2025
- Dividend Yield
- PRFX N/A
- LIPO N/A
- EPS Growth
- PRFX N/A
- LIPO N/A
- EPS
- PRFX N/A
- LIPO N/A
- Revenue
- PRFX N/A
- LIPO $536,357.00
- Revenue This Year
- PRFX N/A
- LIPO N/A
- Revenue Next Year
- PRFX N/A
- LIPO N/A
- P/E Ratio
- PRFX N/A
- LIPO N/A
- Revenue Growth
- PRFX N/A
- LIPO 19.29
- 52 Week Low
- PRFX $0.43
- LIPO $2.02
- 52 Week High
- PRFX $16.63
- LIPO $12.00
- Technical
- Relative Strength Index (RSI)
- PRFX 36.25
- LIPO 48.75
- Support Level
- PRFX $2.12
- LIPO $2.13
- Resistance Level
- PRFX $2.79
- LIPO $2.71
- Average True Range (ATR)
- PRFX 0.17
- LIPO 0.21
- MACD
- PRFX -0.04
- LIPO 0.05
- Stochastic Oscillator
- PRFX 21.69
- LIPO 77.46
About PRFX PainReform Ltd.
PainReform Ltd is a clinical-stage specialty pharmaceutical company. It is focused on the reformulation of established therapeutics. The company's product PRF-110 is based on the local anesthetic ropivacaine, targeting the post-operative pain relief market. PRF-110 is an oil-based, viscous, clear solution that is deposited directly into the surgical wound bed before closure to provide localized and extended post-operative analgesia.
About LIPO Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications. The company's product candidates include LP-10, LP-310 and LP-410 which can be helpful in treatment of Hemorrahagic Cystitis, Oral Licen Planus and Oral Graft.